Education
About Us
Working with TipRanks
Follow Us
Hua Medicine (HK:2552)
:2552
2552 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$1.03 - HK$4.17
Previous CloseN/A
Volume1.46M
Average Volume (3M)12.91M
Market Cap
HK$3.11B
Enterprise ValueHK$531.30M
Total Cash (Recent Filing)HK$1.14B
Total Debt (Recent Filing)HK$300.18M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding1,055,588,700
10 Day Avg. Volume14,784,700
30 Day Avg. Volume12,912,301
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$2.51Price Target Upside-21.99% Downside
Rating ConsensusHold
Number of Analyst Covering0
Hua Medicine News
2552 FAQ
What was Hua Medicine ’s price range in the past 12 months?
Hua Medicine lowest stock price was HK$1.03 and its highest was HK$4.17 in the past 12 months.
What is Hua Medicine ’s market cap?
Hua Medicine ’s market cap is HK$3.11B.
When is Hua Medicine ’s upcoming earnings report date?
Hua Medicine ’s upcoming earnings report date is Aug 21, 2025 which is in 15 days.
How were Hua Medicine ’s earnings last quarter?
Hua Medicine released its earnings results on Mar 27, 2025. The company reported -HK$0.119 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.119.
Is Hua Medicine overvalued?
According to Wall Street analysts Hua Medicine ’s price is currently Overvalued.
Does Hua Medicine pay dividends?
Hua Medicine does not currently pay dividends.
What is Hua Medicine ’s EPS estimate?
Hua Medicine ’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hua Medicine have?
Hua Medicine has 1,055,588,700 shares outstanding.
What happened to Hua Medicine ’s price movement after its last earnings report?
Hua Medicine reported an EPS of -HK$0.119 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.738%.
Which hedge fund is a major shareholder of Hua Medicine ?
Currently, no hedge funds are holding shares in HK:2552
Company Description
Hua Medicine
Hua Medicine (2552) is a biopharmaceutical company based in China, focusing on the development and commercialization of novel therapies for diabetes. The company is renowned for its innovative drug, dorzagliatin, which aims to address the unmet medical needs of type 2 diabetes patients. Hua Medicine operates within the pharmaceutical and biotechnology sectors and is dedicated to advancing healthcare solutions through cutting-edge research and development.
2552 Company Deck
2552 Earnings Call
Q4 2025
0:00 / 0:00
Technical Analysis
Essex Bio-Technology
―
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Jacobson Pharma Corporation Limited
―
China Shineway Pharmaceutical Group Limited
―
Ownership Overview
―
Insiders
0.45%
Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---